Insider trade

CEO exercised or converted 2.27M ROIV derivative securities

Traded Dec 15, 2025 · Filed Dec 18, 2025

Roivant SciencesROIV

2.27M
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 15, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 18, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001140361-25-045906

Filed / recorded

Dec 18, 2025, 7:00 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Roivant Sciences Ltd.

Issuer CIK

1635088

Ticker

ROIV

Reporting person

Matthew Gline

Relationship

Director, Officer

Officer title

CEO

Security

Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Dec 15, 2025

Transaction code

M

Shares / units

2,272,852

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

0

Ownership form

Direct

Amendment

No

Footnotes from the filing

Award of stock options to purchase Common Shares that is fully vested.

Around the same time

200KShares · @ $3.85

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record

CEO sold ~$4.38M of Roivant Sciences

Automatic sale9mo ago

200KDerivative units

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record